Clinical trials: Androgens
Prostate
Otago Exercises on the Risk of Falling in Prostatic Cancer Patients Receiving Androgen Deprivation Therapy
Androgen deprivation therapy (ADT) is a common treatment for older men with advanced prostate cancer (PCa) but is associated with numerous deleterious health effects that may accentuate age associated physiological declines.
- Trial name
- NCT06605846
- Testing
- otago excercises, Medical ADT treatment
- Where
- Egypt
- Volunteers
- 110 people
- Sponsor
- MTI University
NSCLC, Stage III, NSCLC, Stage IV
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies.
- Trial name
- NCT06512207
- Testing
- Leuprorelin acetate + Sintilimab, Sintilimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jinzhou Medical University
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer…
- Trial name
- TulmiSTAR-02 (NCT07190300)
- Testing
- Tulmimetostat, Darolutamide, Abiraterone
- Where
- 31 sites in United States, Australia and 12 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
This Phase II, single arm study evaluates a PSA-response-adapted approach to salvage radiotherapy after radical prostatectomy for prostate cancer.
- Trial name
- (RANGER) (NCT07313241)
- Testing
- Prostate Fossa Radiotherapy, Pelvic nodal Radiotherapy, Androgen Deprivation Therapy (ADT)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Calcitriol may cause prostate cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as mitoxantrone and prednisone, work in different ways to stop the growth…
- Trial name
- NCT00182741
- Testing
- calcitriol, mitoxantrone hydrochloride, prednisone
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Adenocarcinoma
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
This trial studies how well increasing the dose of survivorship care planning improves care and outcomes in prostate cancer survivors receiving radiation therapy and androgen deprivation therapy.
- Trial name
- NCT03860961
- Testing
- Survivorship Care Plan, Treatment Plan
- Where
- 79 sites in United States
- Volunteers
- 550 people
- Sponsor
- NRG Oncology
Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency
AR, IGF-IR, IR and Peripheral Artery Disease
Peripheral artery Disease (PAD) is a major cardiovascular disease that can impair quality of life (QoL). It affects more often male patients and its pathophysiology is not completely known.
- Conditions
- Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency, Insulin Receptor, Defect in
- Trial name
- ANIMALPAD (NCT04710186)
- Testing
- arterial reconstructive open surgery
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Catanzaro
PCOS, NAFLD
Androgens and NAFLD Longitudinal Cohort Study
The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time.
- Conditions
- PCOS, NAFLD, NASH
- Trial name
- NCT06124261
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
This was an extension study for the study FE200486 CS14 (NCT00116779). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained.
- Trial name
- NCT00117286
- Testing
- Degarelix
- Where
- 22 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
This phase II trial studies how well a short course of androgen deprivation therapy (ADT) with relugolix works in increasing expression of prostate-specific membrane antigen (PSMA) and improving diagnostic imaging with PSMA…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT07025369
- Testing
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
This is a a pilot study to assess the feasibility of intermittent caloric restriction (plus a plant-enriched diet optionally) in prostate cancer patients receiving androgen deprivation therapy.
- Trial name
- NCT06172283
- Testing
- Intermittent Fasting
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- State University of New York at Buffalo
Prostate Cancer
Study of Individualized Amonafide to Treat Prostate Cancer
The purpose of this study is to assess the safety and efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to individualized doses of Amonafide based on acetylator phenotype information (doses adjusted…
- Trial name
- NCT00087854
- Testing
- Amonafide L-malate (drug)
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Xanthus Pharmaceuticals, Inc.
Prostate Cancer
Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
- Trial name
- GAINPCCONTROL (NCT06908694)
- Testing
- Semaglutide Pen Injector
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Prostate Cancer
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy…
- Trial name
- NCT04946370
- Testing
- 225Ac-J591, Pembrolizumab, Androgen receptor inhibitor
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).
- Trial name
- NCT00668642
- Testing
- Dutasteride
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Health
Prostate Cancer (Adenocarcinoma), Erectile Abnormalities
PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer
This study looks at how combined radiation and hormone therapy affects sexual function in men with a specific type of prostate cancer, before and after treatment.
- Conditions
- Prostate Cancer (Adenocarcinoma), Erectile Abnormalities, Sexual Dysfunction Male
- Trial name
- PRIAPUS-PCa (NCT07460726)
- Testing
- SBRT combined with ADT
- Where
- Canada
- Volunteers
- 130 people
- Sponsor
- CancerCare Manitoba
Heart Diseases
CardioTOxicity Induced by andRogeNICS and Their Antagonists (TORNICS)
Anti-androgenic therapies relying on peripheral and/or central blockade for the treatment of prostate cancer seems to have an impact on the cardio-vascular system.
- Trial name
- TORNICS (NCT03193138)
- Testing
- Hormonal therapies: G03, H01C and L02 in the ATC classification
- Where
- France
- Volunteers
- 3,096 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Prostatic Neoplasms
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment to improve overall survival for intermediate- and high-risk localized disease as well as metastatic disease.
- Trial name
- NCT04248621
- Testing
- Leuprorelin, Goserelin, Triptorelin
- Where
- 10 sites in South Korea
- Volunteers
- 164 people
- Sponsor
- Wonju Severance Christian Hospital
Prostatic Adenocarcinoma
An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma
Although surgical or medical castration (i.e., androgen-deprivation therapy, ADT) is considered standard treatment in metastatic castration-naïve PC (mCNPC) patients, current guidelines have established the addition docetaxel or…
- Trial name
- NCT06015321
- Testing
- Enzalutamide
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Samsung Medical Center
Psoriasis Vulgaris
Hormonal Associations in Male Patients With Psoriasis Vulgaris
A cross sectional clinical study will be conducted on male patients with moderate and sever psoriasis vulgaris to: Identify the pattern of serum testosterone level and tissue androgen receptors.
- Trial name
- NCT05716152
- Testing
- Morning blood sample and skin punch biopsy of 4 mm diameter.
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Sohag University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.